Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ovid Therapeutics Inc. (OVID)
USD2.50
+0.04 (+1.63%)
US NASDAQ Healthcare Biotechnology
Address
1460 Broadway 10036
New York City, NY, US
New York City, NY, US
CEO
Margaret Alexander
Website
ovidrx.com
IPO
2017-05-05
CIK 1636651 ISIN US6904691010
Description
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.50
+0.04 (+1.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.18
Float Shares
113.96M
Free Float %
86.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.44% | +1.08% | +0.36% | +97.18% | +133.33% | +71.78% | +879.02% | -19.77% | -15.15% | -77.14% | -77.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
2.50
Low
3.00
+20.0%
Consensus
3.50
+40.0%
Median
3.50
+40.0%
High
4.00
+60.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 10 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
4.00
+60.0%
|
| Last Year | 3 |
3.00
+20.0%
|
| All Time | 6 |
5.17
+106.8%
|
Quality scores
Altman Z-Score
6.07
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+1,181.3% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+35.1% ★ Q1'26: +14.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-637.7%
-
EBIT margin Biotechnology: +0.0%-585.2%
-
ROIC Biotechnology: -16.1%-57.0% Q1'26: -161.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.0% Q1'26: +91.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.32× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 8 EPS Ana. |
Dec 2027 5 Rev. Ana. 7 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.62M
est: 11.08M (+13.9%)
|
208.38M
est: 208.39M (0.0%)
|
1.50M
est: 1.47M (+2.4%)
|
392.0K
est: 567.7K (-30.9%)
|
566.0K
est: 662.8K (-14.6%)
|
7.25M
est: 6.60M (+9.9%)
|
221.9K
75.0K – 362.2K
-96.6% YoY
|
237.5K
82.5K – 366.1K
+7.0% YoY
|
230.0K
226.0K – 234.0K
-3.2% YoY
|
10.75M
3.68M – 17.04M
+4,572.8% YoY
|
71.58M
24.54M – 113.51M
+566.0% YoY
|
| EBITDA |
-81.12M
est: -7.54M (-976.0%)
|
124.45M
est: -141.82M (+187.7%)
|
-54.17M
est: -998.5K (-5,324.6%)
|
-57.01M
est: -386.3K (-14,656.9%)
|
-57.77M
est: -451.1K (-12,708.1%)
|
-42.14M
est: -4.49M (-838.7%)
|
-151.0K
-246.5K – -51.1K
+96.6% YoY
|
-161.6K
-249.2K – -56.1K
-7.0% YoY
|
-156.5K
-159.3K – -153.8K
+3.2% YoY
|
-7.31M
-11.60M – -2.51M
-4,572.8% YoY
|
-48.71M
-77.25M – -16.70M
-566.0% YoY
|
| EBIT |
-81.43M
est: -7.54M (-979.7%)
|
124.21M
est: -141.87M (+187.6%)
|
-55.55M
est: -998.9K (-5,461.1%)
|
-57.58M
est: -386.5K (-14,798.9%)
|
-58.39M
est: -451.2K (-12,839.7%)
|
-42.44M
est: -4.49M (-845.1%)
|
-151.0K
-246.6K – -51.1K
+96.6% YoY
|
-161.7K
-249.3K – -56.1K
-7.0% YoY
|
-156.6K
-159.3K – -153.9K
+3.2% YoY
|
-7.32M
-11.60M – -2.51M
-4,572.8% YoY
|
-48.73M
-77.27M – -16.71M
-566.0% YoY
|
| Net Income |
-81.04M
est: -95.66M (+15.3%)
|
122.83M
est: 143.10M (-14.2%)
|
-54.17M
est: -53.35M (-1.5%)
|
-52.34M
est: -29.75M (-75.9%)
|
-26.43M
est: -34.29M (+22.9%)
|
-17.41M
est: -36.70M (+52.6%)
|
-63.42M
-77.00M – -25.17M
-72.8% YoY
|
-84.39M
-91.77M – -24.00M
-33.1% YoY
|
-61.83M
-95.66M – -28.01M
+26.7% YoY
|
-49.72M
-87.58M – -7.25M
+19.6% YoY
|
-12.99M
-22.88M – -1.89M
+73.9% YoY
|
| SGA |
30.63M
est: 321.36M (-90.5%)
|
37.23M
est: 6.04B (-99.4%)
|
32.43M
est: 42.56M (-23.8%)
|
29.59M
est: 16.57M (+78.6%)
|
25.68M
est: 19.34M (+32.8%)
|
24.11M
est: 192.52M (-87.5%)
|
6.48M
2.19M – 10.57M
-96.6% YoY
|
6.93M
2.41M – 10.69M
+7.0% YoY
|
6.71M
6.60M – 6.83M
-3.2% YoY
|
313.68M
107.55M – 497.41M
+4,572.8% YoY
|
2.09B
716.29M – 3.31B
+566.0% YoY
|
| EPS |
-1.39
est: -1.35 (-3.0%)
|
1.78
est: 2.02 (-11.8%)
|
-0.77
est: -0.75 (-2.3%)
|
-0.74
est: -0.42 (-76.0%)
|
-0.37
est: -0.47 (+20.4%)
|
-0.24
est: -0.48 (+49.7%)
|
-0.49
-1.04 – -0.34
-3.1% YoY
|
-0.57
-1.24 – -0.33
-16.8% YoY
|
-0.74
-1.30 – -0.38
-28.2% YoY
|
-0.67
-1.19 – -0.10
+8.5% YoY
|
-0.18
-0.31 – -0.03
+73.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-37.05M
OE per share TTM
-0.50
Owner's Yield
-16.26%
Maintenance CapEx ratio
1.28%
Maint CapEx / Avg PPE
19.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
28
Total invested
26.34M
Insider transactions (90d)
0
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David Rosen | 6.83M | 9.69% | — | 6.83M | — | — | IN | United States of America | 2023-02-10 | ↗ |
| 2 | Rubric Capital Management LP | 6.83M | 9.69% | — | 6.83M | — | — | IA, PN | State of Delaware | 2023-02-10 | ↗ |
| 3 | M. Levin | 6.55M | 9.40% | 6.55M | — | 6.55M | — | IN | States of America | 2022-02-14 | ↗ |
| 4 | Jeremy M. Levin | 6.09M | 9.60% | 6.09M | — | 6.09M | — | IN | United States of America | 2021-02-16 | ↗ |
| 5 | EcoR1 Capital, LLC | 6.08M | 11.00% | — | 6.08M | — | 6.08M | IA, OO | Delaware | 2022-02-14 | ↗ |
| 6 | Oleg Nodelman | 6.08M | 11.00% | — | 6.08M | — | 6.08M | HC, IN | United States | 2022-02-14 | ↗ |
| 7 | EcoR1 Capital Fund Qualified, L.P. | 5.53M | 11.00% | — | 5.53M | — | 5.53M | PN | Delaware | 2022-02-14 | ↗ |
| 8 | BVF Inc. | 4.52M | 6.90% | — | — | — | 4.52M | CO | — | 2021-02-12 | ↗ |
| 9 | BVF Partners L.P. | 4.52M | 6.90% | — | — | — | 4.52M | IA, PN | — | 2021-02-12 | ↗ |
| 10 | Mark N. Lampert | 4.52M | 6.90% | — | — | — | 4.52M | IN | — | 2021-02-12 | ↗ |
| 11 | (1) BlackRock, Inc. | 4.32M | 6.10% | 4.25M | — | 4.32M | — | HC | Delaware | 2024-01-29 | ↗ |
| 12 | BVF GP HOLDINGS LLC | 4.15M | 6.30% | — | — | — | 4.15M | OO | — | 2021-02-12 | ↗ |
| 13 | Jon M. Plexico | 4.01M | 11.00% | 4.01M | — | 4.01M | — | HC, IN | U.S.A. | 2022-02-14 | ↗ |
| 14 | Stonepine Capital Management, LLC | 4.01M | 11.00% | 4.01M | — | 4.01M | — | IA, OO | California | 2022-02-14 | ↗ |
| 15 | Stonepine Capital, L.P. | 4.01M | 11.00% | 4.01M | — | 4.01M | — | PN | Delaware | 2022-02-14 | ↗ |
| 16 | Timothy P. Lynch | 4.01M | 11.00% | 4.01M | — | 4.01M | — | HC, IN | U.S.A. | 2022-02-14 | ↗ |
| 17 | Caraway Jackson Investments LLC | 3.61M | 5.10% | — | 3.61M | — | 3.61M | OO | Cayman Islands | 2023-07-31 | ↗ |
| 18 | EMAI Management, LLC | 3.61M | 5.10% | — | 3.61M | — | 3.61M | OO | Cayman Islands | 2023-07-31 | ↗ |
| 19 | Eli Samaha | 3.61M | 5.10% | — | 3.61M | — | 3.61M | IN | Cayman Islands | 2023-07-31 | ↗ |
| 20 | Madison Avenue GP, LLC | 3.61M | 5.10% | — | 3.61M | — | 3.61M | OO | Cayman Islands | 2023-07-31 | ↗ |
| 21 | Madison Avenue International LP | 3.61M | 5.10% | — | 3.61M | — | 3.61M | OO | Cayman Islands | 2023-07-31 | ↗ |
| 22 | Madison Avenue Partners, LP | 3.61M | 5.10% | — | 3.61M | — | 3.61M | OO | Cayman Islands | 2023-07-31 | ↗ |
| 23 | The Vanguard Group - 23-1945930 | 3.44M | 5.06% | — | 7.8K | — | 19.6K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 24 | During | 3.10M | 4.50% | 3.10M | — | 3.10M | — | IN | States of America | 2022-02-14 | ↗ |
| 25 | BVF I GP LLC | 2.41M | 3.70% | — | — | — | 2.41M | OO | — | 2021-02-12 | ↗ |
| 26 | Biotechnology Value Fund, L.P. | 2.41M | 3.70% | — | — | — | 2.41M | PN | — | 2021-02-12 | ↗ |
| 27 | BVF II GP LLC | 1.74M | 2.70% | — | — | — | 1.74M | OO | — | 2021-02-12 | ↗ |
| 28 | Biotechnology Value Fund II, L.P. | 1.74M | 2.70% | — | — | — | 1.74M | PN | — | 2021-02-12 | ↗ |
| 29 | BVF Partners OS Ltd. | 292.0K | 1.00% | — | — | — | 292.0K | CO | — | 2021-02-12 | ↗ |
| 30 | Biotechnology Value Trading Fund OS LP | 292.0K | 1.00% | — | — | — | 292.0K | PN | — | 2021-02-12 | ↗ |
| 31 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 32 | Consonance Capital Opportunity Fund Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2021-02-17 | ↗ |
| 33 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware USA | 2021-02-17 | ↗ |
| 34 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | USA | 2021-02-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
28
-62 vs prev Q
New positions
6
Closed positions
63
Increased
12
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 10.71M +10.7M (+100.0%) | 17.46M +17.5M (+100.0%) | 15.07% +15.067 pp | 0.18% +0.179 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 2 | AFFINITY ASSET ADVISORS, LLC | 7.15M +4.5M (+169.8%) | 11.65M +8.2M (+238.3%) | 10.05% +6.328 pp | 0.66% +0.364 pp | USD1.42 +14.8% | 4 qtrs — |
| 3 | EVENTIDE ASSET MANAGEMENT, LLC | 4.29M +4.3M (+100.0%) | 6.98M +7.0M (+100.0%) | 6.03% +6.026 pp | 0.11% +0.109 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 4 | ADAR1 CAPITAL MANAGEMENT, LLC | 4.29M +4.3M (+33,256.7%) | 6.98M +7.0M (+41,723.7%) | 6.03% +6.008 pp | 0.51% +0.511 pp | USD1.63 +0.0% | 9 qtrs — |
| 5 | POINT72 ASSET MANAGEMENT, L.P. | 3.55M +3.6M (+100.0%) | 5.79M +5.8M (+100.0%) | 4.99% +4.994 pp | 0.01% +0.007 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.49M +2.1M (+158.7%) | 5.69M +3.9M (+224.3%) | 4.91% +3.012 pp | 0.01% +0.006 pp | USD1.36 +19.9% | 5 qtrs — |
| 7 | FEDERATED HERMES, INC. | 3.57M +3.6M (+100.0%) | 5.31M +5.3M (+100.0%) | 5.02% +5.022 pp | 0.01% +0.009 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 8 | VANGUARD GROUP INC | 3.07M +251.4K (+8.9%) | 5.01M +1.3M (+36.6%) | 4.32% +0.354 pp | 0.00% +0.000 pp | USD3.57 -54.3% | 35 qtrs — |
| 9 | SATURN V CAPITAL MANAGEMENT LLC | 2.50M +2.5M (+100.0%) | 4.08M +4.1M (+100.0%) | 3.52% +3.516 pp | 0.75% +0.748 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 10 | ALLY BRIDGE GROUP (NY) LLC | 1.79M +1.8M (+100.0%) | 2.91M +2.9M (+100.0%) | 2.51% +2.510 pp | 3.03% +3.031 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 1.48M -533.5K (-26.4%) | 2.42M -203.7K (-7.8%) | 2.09% -0.750 pp | 0.00% +0.000 pp | USD0.40 +307.5% | 18 qtrs — |
| 12 | SIO CAPITAL MANAGEMENT, LLC | 1.43M +— (+0.0%) | 2.33M +471.1K (+25.4%) | 2.01% +0.000 pp | 0.37% -0.104 pp | USD0.59 +176.3% | 5 qtrs — |
| 13 | MILLENNIUM MANAGEMENT LLC | 1.34M +353.2K (+35.8%) | 2.18M +901.1K (+70.3%) | 1.88% +0.497 pp | 0.00% +0.000 pp | USD0.67 +143.3% | 3 qtrs — |
| 14 | MARSHALL WACE, LLP | 1.27M +487.8K (+62.3%) | 2.07M +1.1M (+103.4%) | 1.79% +0.686 pp | 0.00% +0.001 pp | USD1.30 +25.4% | 3 qtrs — |
| 15 | ACADIAN ASSET MANAGEMENT LLC | 1.23M -1.1M (-46.1%) | 2.01M -964.0K (-32.4%) | 1.73% -1.483 pp | 0.00% -0.002 pp | USD2.83 -42.4% | 32 qtrs — |
| 16 | AWM INVESTMENT COMPANY, INC. | 899.2K +899.2K (+100.0%) | 1.47M +1.5M (+100.0%) | 1.26% +1.265 pp | 0.14% +0.142 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 17 | JANE STREET GROUP, LLC | 883.9K +645.5K (+270.7%) | 1.44M +1.1M (+364.8%) | 1.24% +0.908 pp | 0.00% +0.000 pp | USD1.38 +18.1% | 9 qtrs — |
| 18 | WELLS FARGO & COMPANY/MN | 720.8K -9.9K (-1.4%) | 1.17M +225.1K (+23.7%) | 1.01% -0.014 pp | 0.00% +0.000 pp | USD1.82 -10.4% | 34 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 672.0K +24.0K (+3.7%) | 1.10M +253.0K (+30.0%) | 0.95% +0.034 pp | 0.00% +0.000 pp | USD3.64 -55.2% | 35 qtrs — |
| 20 | ASSENAGON ASSET MANAGEMENT S.A. | 618.0K -306.6K (-33.2%) | 1.01M -194.6K (-16.2%) | 0.87% -0.431 pp | 0.00% 0.000 pp | USD0.89 +83.1% | 9 qtrs — |
| 21 | BLACKROCK, INC. | 613.5K +2.2K (+0.4%) | 1,000.0K +205.3K (+25.8%) | 0.86% +0.003 pp | 0.00% +0.000 pp | USD1.18 +38.1% | 6 qtrs — |
| 22 | TWO SIGMA INVESTMENTS, LP | 598.9K +257.7K (+75.6%) | 976.2K +532.7K (+120.1%) | 0.84% +0.362 pp | 0.00% +0.001 pp | USD1.44 +13.2% | 2 qtrs — |
| 23 | WALLEYE CAPITAL LLC | 530.0K -66.7K (-11.2%) | 863.9K +88.2K (+11.4%) | 0.75% -0.094 pp | 0.00% 0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 341.7K -247.4K (-42.0%) | 557.0K -208.8K (-27.3%) | 0.48% -0.348 pp | 0.00% +0.000 pp | USD0.97 +68.0% | 5 qtrs — |
| 25 | BALYASNY ASSET MANAGEMENT L.P. | 325.0K -300.0K (-48.0%) | 529.8K -282.8K (-34.8%) | 0.46% -0.422 pp | 0.00% 0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 26 | STATE STREET CORP | 276.5K +49.5K (+21.8%) | 450.7K +155.6K (+52.7%) | 0.39% +0.070 pp | 0.00% +0.000 pp | USD2.90 -43.8% | 23 qtrs — |
| 27 | IKARIAN CAPITAL, LLC | 247.6K -848.0K (-77.4%) | 403.5K -1.0M (-71.7%) | 0.35% -1.193 pp | 0.03% -0.112 pp | USD1.30 +25.4% | 2 qtrs — |
| 28 | TWO SIGMA ADVISERS, LP | 239.2K +87.4K (+57.6%) | 389.9K +192.6K (+97.6%) | 0.34% +0.123 pp | 0.00% +0.000 pp | USD1.42 +14.8% | 2 qtrs — |
| 29 | TLS ADVISORS LLC | 13.6K -5.3K (-27.9%) | 374.0K +348.0K (+1,338.5%) | 0.02% -0.007 pp | 0.98% +0.905 pp | USD1.86 -12.4% | 13 qtrs — |
| 30 | PARKMAN HEALTHCARE PARTNERS LLC | 201.0K -1.9K (-1.0%) | 327.7K +63.8K (+24.2%) | 0.28% -0.003 pp | 0.03% +0.004 pp | USD1.30 +25.4% | 2 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 194.9K -167.8K (-46.3%) | 317.7K -153.8K (-32.6%) | 0.27% -0.236 pp | 0.00% +0.000 pp | USD1.32 +23.5% | 34 qtrs — |
| 32 | UBS GROUP AG | 193.0K -45.0K (-18.9%) | 314.6K +5.2K (+1.7%) | 0.27% -0.063 pp | 0.00% +0.000 pp | USD1.34 +21.6% | 34 qtrs — |
| 33 | SCHONFELD STRATEGIC ADVISORS LLC | 192.5K -690.7K (-78.2%) | 313.8K -834.3K (-72.7%) | 0.27% -0.971 pp | 0.00% -0.005 pp | USD1.30 +25.4% | 2 qtrs — |
| 34 | XTX TOPCO LTD | 188.5K +5.2K (+2.8%) | 307.2K +68.9K (+28.9%) | 0.27% +0.007 pp | 0.01% -0.004 pp | USD0.90 +81.1% | 7 qtrs — |
| 35 | GOLDMAN SACHS GROUP INC | 170.5K +141.9K (+497.7%) | 277.8K +240.8K (+649.5%) | 0.24% +0.200 pp | 0.00% +0.000 pp | USD1.49 +9.4% | 32 qtrs — |
| 36 | NORTHERN TRUST CORP | 166.6K +14.9K (+9.8%) | 271.6K +74.4K (+37.7%) | 0.23% +0.021 pp | 0.00% +0.000 pp | USD2.75 -40.7% | 35 qtrs — |
| 37 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 160.0K +— (+0.0%) | 260.8K +52.8K (+25.4%) | 0.23% +0.000 pp | 0.15% -0.044 pp | USD0.59 +176.3% | 5 qtrs — |
| 38 | BOOTHBAY FUND MANAGEMENT, LLC | 155.7K -331.1K (-68.0%) | 253.9K -379.1K (-59.9%) | 0.22% -0.466 pp | 0.00% -0.005 pp | USD1.30 +25.4% | 2 qtrs — |
| 39 | GRAHAM CAPITAL MANAGEMENT, L.P. | 127.5K +127.5K (+100.0%) | 207.8K +207.8K (+100.0%) | 0.18% +0.179 pp | 0.01% +0.005 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 40 | OMERS ADMINISTRATION CORP | 125.3K +125.3K (+100.0%) | 204.2K +204.2K (+100.0%) | 0.18% +0.176 pp | 0.00% +0.002 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 41 | GSA CAPITAL PARTNERS LLP | 108.3K -157.7K (-59.3%) | 177.0K -169.0K (-48.8%) | 0.15% -0.222 pp | 0.02% -0.014 pp | USD0.44 +270.5% | 7 qtrs — |
| 42 | CITADEL ADVISORS LLC | 106.9K +28.4K (+36.2%) | 174.2K +72.2K (+70.7%) | 0.15% +0.040 pp | 0.00% +0.000 pp | USD1.26 +29.4% | 23 qtrs — |
| 43 | STONEPINE CAPITAL MANAGEMENT, LLC | 102.4K +102.4K (+100.0%) | 166.9K +166.9K (+100.0%) | 0.14% +0.144 pp | 0.12% +0.122 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 44 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 95.4K +— (+0.0%) | 155.6K +31.5K (+25.4%) | 0.13% +0.000 pp | 0.00% +0.001 pp | USD2.71 -39.9% | 20 qtrs — |
| 45 | EMPOWERED FUNDS, LLC | 91.2K +— (+0.0%) | 148.7K +30.1K (+25.4%) | 0.13% +0.000 pp | 0.00% +0.000 pp | USD3.03 -46.2% | 11 qtrs — |
| 46 | QUADRATURE CAPITAL LTD | 87.9K +60.2K (+217.2%) | 143.2K +107.4K (+299.3%) | 0.12% +0.085 pp | 0.00% +0.001 pp | USD1.53 +6.5% | 2 qtrs — |
| 47 | BANK OF NEW YORK MELLON CORP | 57.7K +— (+0.0%) | 94.0K +19.0K (+25.4%) | 0.08% +0.000 pp | 0.00% +0.000 pp | USD3.58 -54.5% | 24 qtrs — |
| 48 | QUBE RESEARCH & TECHNOLOGIES LTD | 54.0K +28.7K (+113.4%) | 87.9K +55.1K (+167.6%) | 0.08% +0.040 pp | 0.00% +0.000 pp | USD1.02 +59.8% | 3 qtrs — |
| 49 | FMR LLC | 44.0K -3.0K (-6.4%) | 71.7K +10.6K (+17.3%) | 0.06% -0.004 pp | 0.00% +0.000 pp | USD0.95 +71.6% | 18 qtrs — |
| 50 | SQUAREPOINT OPS LLC | 39.0K -75.9K (-66.0%) | 63.6K -85.8K (-57.4%) | 0.05% -0.107 pp | 0.00% 0.000 pp | USD0.31 +425.8% | 4 qtrs — |
| 51 | MORGAN STANLEY | 37.0K +34.6K (+1,496.9%) | 60.2K +57.2K (+1,902.4%) | 0.05% +0.049 pp | 0.00% +0.000 pp | USD1.64 -0.6% | 35 qtrs — |
| 52 | INVESCO LTD. | 33.3K +33.3K (+100.0%) | 54.3K +54.3K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 53 | SIMPLEX TRADING, LLC | 31.6K -355.9K (-91.8%) | 51.5K -451.5K (-89.8%) | 0.04% -0.501 pp | 0.00% 0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 54 | ABEL HALL, LLC | 31.4K -921.0 (-2.8%) | 51.2K +9.2K (+21.8%) | 0.04% -0.001 pp | 0.01% -0.005 pp | USD0.32 +409.4% | 4 qtrs — |
| 55 | LPL FINANCIAL LLC | 30.0K +18.0K (+150.0%) | 48.9K +33.3K (+213.5%) | 0.04% +0.025 pp | 0.00% +0.000 pp | USD1.50 +8.7% | 2 qtrs — |
| 56 | TOTAL CLARITY WEALTH MANAGEMENT, INC. | 28.6K +28.6K (+100.0%) | 46.6K +46.6K (+100.0%) | 0.04% +0.040 pp | 0.01% +0.011 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 57 | BLAIR WILLIAM & CO/IL | 26.3K +1.3K (+5.0%) | 42.9K +10.3K (+31.6%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD3.49 -53.3% | 25 qtrs — |
| 58 | FIRST MANHATTAN CO. LLC. | 26.0K +— (+0.0%) | 42.4K +8.6K (+25.4%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD3.23 -49.5% | 26 qtrs — |
| 59 | BENIN MANAGEMENT CORP | 19.0K +19.0K (+100.0%) | 31.0K +31.0K (+100.0%) | 0.03% +0.027 pp | 0.01% +0.007 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 60 | CETERA INVESTMENT ADVISERS | 17.0K +1.0 (+0.0%) | 27.7K +5.6K (+25.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 61 | NINE MASTS CAPITAL LTD | 14.0K +14.0K (+100.0%) | 22.8K +22.8K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.004 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 62 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 11.3K +— (+0.0%) | 18.7K +3.3K (+21.2%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD0.33 +393.9% | 3 qtrs — |
| 63 | AARON WEALTH ADVISORS LLC | 11.2K +— (+0.0%) | 18.3K +3.7K (+25.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD0.33 +393.9% | 3 qtrs — |
| 64 | TOWER RESEARCH CAPITAL LLC (TRC) | 10.7K +8.3K (+355.5%) | 17.4K +14.4K (+471.1%) | 0.02% +0.012 pp | 0.00% +0.000 pp | USD1.44 +13.2% | 34 qtrs — |
| 65 | SEPIO CAPITAL, LP | 10.1K +10.1K (+100.0%) | 16.5K +16.5K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.001 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 66 | SOVEREIGN FINANCIAL GROUP, INC. | 10.0K +— (+0.0%) | 16.3K +3.3K (+25.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 67 | CITIGROUP INC | 4.7K +3.9K (+484.3%) | 7.7K +6.6K (+632.9%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 35 qtrs — |
| 68 | QUADCAP WEALTH MANAGEMENT, LLC | 4.0K +— (+0.0%) | 6.5K +1.3K (+25.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 69 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 4.0K +4.0K (+100.0%) | 6.5K +6.5K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 70 | CLEARSTEAD ADVISORS, LLC | 2.7K +2.7K (+100.0%) | 4.5K +4.5K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 71 | NISA INVESTMENT ADVISORS, LLC | 2.4K +— (+0.0%) | 3.8K +776.0 (+25.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.43 +279.1% | 7 qtrs — |
| 72 | ATLANTIC UNION BANKSHARES CORP | 2.3K +— (+0.0%) | 3.7K +759.0 (+25.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.33 +393.9% | 3 qtrs — |
| 73 | ROYAL BANK OF CANADA | 1.1K -3.5K (-76.5%) | 2.0K -4.0K (-66.7%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD0.71 +129.6% | 11 qtrs — |
| 74 | NORTH STAR INVESTMENT MANAGEMENT CORP. | 1.0K +— (+0.0%) | 1.7K +344.0 (+25.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 75 | TFC FINANCIAL MANAGEMENT, INC. | 1.0K +1.0K (+100.0%) | 1.6K +1.6K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 76 | BNP PARIBAS ARBITRAGE, SNC | 980.00 +18.0 (+1.9%) | 1.6K +346.0 (+27.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.24 +31.5% | 35 qtrs — |
| 77 | PNC FINANCIAL SERVICES GROUP, INC. | 903.00 +— (+0.0%) | 1.5K +298.0 (+25.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.33 +393.9% | 5 qtrs — |
| 78 | SBI SECURITIES CO., LTD. | 189.00 -236.0 (-55.5%) | 308.00 -245.0 (-44.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.37 +340.5% | 5 qtrs — |
| 79 | JPMORGAN CHASE & CO | 147.00 -2.8K (-95.0%) | 240.00 -3.6K (-93.7%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD3.81 -57.2% | 33 qtrs — |
| 80 | TRADEWINDS CAPITAL MANAGEMENT, LLC | 100.00 +100.0 (+100.0%) | 163.00 +163.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 81 | SRS CAPITAL ADVISORS, INC. | 57.00 -83.0 (-59.3%) | 93.00 -89.0 (-48.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.30 +25.4% | 2 qtrs — |
| 82 | SAGEVIEW ADVISORY GROUP, LLC | 44.00 +44.0 (+100.0%) | 72.00 +72.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.61 +1.2% | 1 qtrs NEW |
| 83 | TD WATERHOUSE CANADA INC. | 30.00 +— (+0.0%) | 49.00 +8.0 (+19.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.17 +39.3% | 6 qtrs — |
| 84 | SOUND INCOME STRATEGIES, LLC | 6.00 +— (+0.0%) | 9.00 -1.0 (-10.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -45.7% | 8 qtrs — |
| 85 | BARCLAYS PLC | 1.00 -84.2K (-100.0%) | 2.00 -99.3K (-100.0%) | 0.00% -0.118 pp | 0.00% +0.000 pp | USD1.00 +63.0% | 11 qtrs — |
| 86 | PRIVATE ADVISOR GROUP, LLC | — -25.6K (-100.0%) | — -33.3K (-100.0%) | 0.00% -0.036 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 87 | KENNEDY CAPITAL MANAGEMENT LLC | — -1.1M (-100.0%) | — -1.4M (-100.0%) | 0.00% -1.556 pp | 0.00% -0.032 pp | USD— | 7 qtrs SOLD |
| 88 | TWO SIGMA SECURITIES, LLC | — -11.7K (-100.0%) | — -15.2K (-100.0%) | 0.00% -0.017 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 89 | DIADEMA PARTNERS LP | — -187.7K (-100.0%) | — -244.1K (-100.0%) | 0.00% -0.264 pp | 0.00% -0.062 pp | USD— | 2 qtrs SOLD |
| 90 | GROUP ONE TRADING, L.P. | — -188.3K (-100.0%) | — -244.8K (-100.0%) | 0.00% -0.265 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 91 | ADVISORY SERVICES NETWORK, LLC | — -219.0 (-100.0%) | — -285.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 92 | ADVISOR GROUP HOLDINGS, INC. | — -5.0 (-100.0%) | — -6.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 23 qtrs SOLD |
| 93 | PERSISTENT ASSET PARTNERS LTD | — -46.0K (-100.0%) | — -59.9K (-100.0%) | 0.00% -0.065 pp | 0.00% -0.041 pp | USD— | 2 qtrs SOLD |
| 94 | INTEGRATED WEALTH CONCEPTS LLC | — -52.9K (-100.0%) | — -68.8K (-100.0%) | 0.00% -0.074 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 95 | DRIEHAUS CAPITAL MANAGEMENT LLC | — -1.4M (-100.0%) | — -1.8M (-100.0%) | 0.00% -1.969 pp | 0.00% -0.013 pp | USD— | 7 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 56 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Biotech ETF XBI | 0.11% | 12.43M | 0.35% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.11% | 40.0K | 0.45% |
| 3 | iShares Micro-Cap ETF IWC | 0.09% | 1.30M | 0.60% |
| 4 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.04% | 460.2K | 0.20% |
| 5 | Pacer WealthShield ETF PWS | 0.02% | 5.8K | 0.60% |
| 6 | iShares Russell 2000 Value ETF IWN | 0.02% | 3.02M | 0.24% |
| 7 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.01% | 99.8K | 0.96% |
| 8 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 426.8K | 0.25% |
| 9 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 378.1K | 0.30% |
| 10 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 39.2K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
890.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+890,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-07 | PAPADOPOULOS STELIOS | Director | A-Award | A | Common Stock | 17,578 | 2.56 | 45.0K | 217,578 | D | ↗ |
| 2026-04-07 | Friedman Bart | Director | A-Award | A | Common Stock | 8,789 | 2.56 | 22.5K | 8,789 | D | ↗ |
| 2026-04-07 | Fitzgerald Kevin Joseph | Director | A-Award | A | Common Stock | 17,578 | 2.56 | 45.0K | 17,578 | D | ↗ |
| 2026-03-23 | LEVIN JEREMY M | Director / Officer | M-Exempt | A | Common Stock | 47,333 | 1.40 | 66.3K | 3,735,048 | D | ↗ |
| 2026-02-26 | Rona Jeffrey A | Officer | A-Award | A | Common Stock | 68,125 | 0.00 | — | 156,313 | D | ↗ |
| 2026-02-26 | PAPADOPOULOS STELIOS | Director | A-Award | A | Employee Stock Option (Right to Buy) | 65,000 | 1.65 | 107.3K | 65,000 | D | ↗ |
| 2026-02-26 | LEVIN JEREMY M | Director | A-Award | A | Employee Stock Option (Right to Buy) | 957,000 | 1.65 | 1.58M | 957,000 | D | ↗ |
| 2026-02-26 | Friedman Bart | Director | A-Award | A | Employee Stock Option (Right to Buy) | 65,000 | 1.65 | 107.3K | 65,000 | D | ↗ |
| 2026-02-26 | Fitzgerald Kevin Joseph | Director | A-Award | A | Employee Stock Option (Right to Buy) | 65,000 | 1.65 | 107.3K | 65,000 | D | ↗ |
| 2026-02-26 | DUNCAN BARBARA GAYLE | Director | A-Award | A | Employee Stock Option (Right to Buy) | 65,000 | 1.65 | 107.3K | 65,000 | D | ↗ |
| 2026-02-26 | Bernstein Karen | Director | A-Award | A | Employee Stock Option (Right to Buy) | 65,000 | 1.65 | 107.3K | 65,000 | D | ↗ |
| 2026-02-26 | ALEXANDER MARGARET A. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,435,000 | 1.65 | 2.37M | 1,435,000 | D | ↗ |
| 2026-02-23 | Rona Jeffrey A | Officer | S-Sale | D | Common Stock | 8,541 | 1.45 | 12.4K | 88,188 | D | ↗ |
| 2026-02-23 | ALEXANDER MARGARET A. | Director / Officer | S-Sale | D | Common Stock | 11,656 | 1.45 | 16.9K | 61,750 | D | ↗ |
| 2026-01-04 | ALEXANDER MARGARET A. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 890,000 | 1.76 | 1.57M | 890,000 | D | ↗ |
| 2025-12-15 | LEVIN JEREMY M | Director / Officer | C-Conversion | A | Common Stock | 71,000 | 0.00 | — | 3,687,715 | D | ↗ |
| 2025-12-11 | LEVIN JEREMY M | Director / Officer | P-Purchase | A | Series A Warrant (right to buy) | 47,333 | 1.40 | 66.3K | 47,333 | D | ↗ |
| 2025-12-08 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 1,250 | 0.00 | — | 0 | I | ↗ |
| 2025-03-03 | PAPADOPOULOS STELIOS | Director | A-Award | A | Stock Option (right to buy) | 90,000 | 0.49 | 44.1K | 90,000 | D | ↗ |
| 2025-03-01 | PAPADOPOULOS STELIOS | Director | — | — | Common Stock | 0 | 0.00 | — | 200,000 | D | ↗ |
| 2025-02-26 | Rona Jeffrey A | Officer | S-Sale | D | Common Stock | 3,902 | 0.56 | 2.2K | 67,973 | D | ↗ |
| 2025-02-26 | ALEXANDER MARGARET A. | Officer | S-Sale | D | Common Stock | 5,279 | 0.56 | 3.0K | 73,406 | D | ↗ |
| 2025-02-20 | Rona Jeffrey A | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 262,500 | 0.57 | 149.6K | 262,500 | D | ↗ |
| 2025-02-20 | LEVIN JEREMY M | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,650,000 | 0.57 | 940.5K | 1,650,000 | D | ↗ |
| 2025-02-20 | Friedman Bart | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.57 | 25.7K | 45,000 | D | ↗ |
| 2025-02-20 | Fitzgerald Kevin Joseph | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.57 | 25.7K | 45,000 | D | ↗ |
| 2025-02-20 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.57 | 25.7K | 45,000 | D | ↗ |
| 2025-02-20 | Bernstein Karen | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 0.57 | 25.7K | 45,000 | D | ↗ |
| 2025-02-20 | ALEXANDER MARGARET A. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 262,500 | 0.57 | 149.6K | 262,500 | D | ↗ |
| 2025-01-27 | ALEXANDER MARGARET A. | Officer | P-Purchase | A | Common Stock | 6,810 | 0.73 | 5.0K | 34,935 | D | ↗ |
| 2024-12-12 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.06 | 95.4K | 90,000 | D | ↗ |
| 2024-12-12 | Fitzgerald Kevin Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.06 | 95.4K | 90,000 | D | ↗ |
| 2024-12-12 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.06 | 95.4K | 90,000 | D | ↗ |
| 2024-12-12 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 1.06 | 95.4K | 90,000 | D | ↗ |
| 2024-09-09 | ALEXANDER MARGARET A. | Officer | — | D | Employee Stock Option (right to buy) | 175,000 | 2.50 | 437.5K | 0 | — | ↗ |
| 2024-07-30 | Rona Jeffrey A | Officer | A-Award | A | Employee Stock Option (right to buy) | 315,000 | 1.05 | 329.2K | 315,000 | — | ↗ |
| 2024-03-18 | LEVIN JEREMY M | Director / Officer | P-Purchase | A | Common Stock | 18,248 | 2.76 | 50.4K | 3,616,715 | — | ↗ |
| 2024-02-22 | Tardio Jason | Officer | A-Award | A | Common Stock | 28,125 | 0.00 | — | 28,125 | — | ↗ |
| 2024-02-22 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 168,750 | 3.68 | 621.0K | 0 | — | ↗ |
| 2024-02-22 | Poole Robert Michael | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.68 | 110.4K | 30,000 | — | ↗ |
| 2024-02-22 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 168,750 | 3.68 | 621.0K | 168,750 | — | ↗ |
| 2024-02-22 | LEVIN JEREMY M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 3.68 | 2.58M | 700,000 | — | ↗ |
| 2024-02-22 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.68 | 110.4K | 30,000 | — | ↗ |
| 2024-02-22 | Fitzgerald Kevin Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.68 | 110.4K | 30,000 | — | ↗ |
| 2024-02-22 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.68 | 110.4K | 30,000 | — | ↗ |
| 2024-02-22 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.68 | 110.4K | 30,000 | — | ↗ |
| 2023-12-04 | LEVIN JEREMY M | Director / Officer | G-Gift | D | Common Stock | 573,275 | 0.00 | — | 4,171,742 | — | ↗ |
| 2023-02-23 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.50 | 437.5K | 175,000 | — | ↗ |
| 2023-02-23 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.50 | 437.5K | 175,000 | — | ↗ |
| 2023-02-23 | Poole Robert Michael | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.50 | 37.5K | 15,000 | — | ↗ |
| 2023-02-23 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.50 | 437.5K | 175,000 | — | ↗ |
| 2023-02-23 | LEVIN JEREMY M | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 600,000 | 2.50 | 1.50M | 600,000 | — | ↗ |
| 2023-02-23 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.50 | 37.5K | 15,000 | — | ↗ |
| 2023-02-23 | Fitzgerald Kevin Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.50 | 37.5K | 15,000 | — | ↗ |
| 2023-02-23 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.50 | 37.5K | 15,000 | — | ↗ |
| 2023-02-23 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.50 | 37.5K | 15,000 | — | ↗ |
| 2022-09-12 | Tardio Jason | Officer | S-Sale | D | Common Stock | 17,344 | 2.15 | 37.3K | 0 | — | ↗ |
| 2022-07-01 | Takeda Pharmaceuticals U.S.A., Inc. | Director | J-Other | A | Series A Convertible Preferred Stock | 1,250 | 0.00 | — | 1,250 | — | ↗ |
| 2022-07-01 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | J-Other | A | Common Stock | 5,750,000 | 0.00 | — | 5,750,000 | — | ↗ |
| 2022-04-08 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-04-08 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 194,399 | 0.00 | — | 194,399 | — | ↗ |
| 2022-04-08 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-04-08 | LEVIN JEREMY M | Officer | A-Award | A | Stock Option (Right to Buy) | 423,244 | 0.00 | — | 423,244 | — | ↗ |
| 2022-04-08 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 69,424 | 0.00 | — | 69,424 | — | ↗ |
| 2022-04-08 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 21,347 | 0.00 | — | 21,347 | — | ↗ |
| 2022-04-08 | Bernstein Karen | Director | A-Award | A | Stock Option (right to buy) | 69,424 | 0.00 | — | 69,424 | — | ↗ |
| 2022-02-03 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.72 | 476.0K | 175,000 | — | ↗ |
| 2022-02-03 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 218,750 | 2.72 | 595.0K | 218,750 | — | ↗ |
| 2022-02-03 | Poole Robert Michael | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.72 | 40.8K | 15,000 | — | ↗ |
| 2022-02-03 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.72 | 476.0K | 175,000 | — | ↗ |
| 2022-02-03 | LEVIN JEREMY M | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 600,000 | 2.72 | 1.63M | 600,000 | — | ↗ |
| 2022-02-03 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.72 | 40.8K | 15,000 | — | ↗ |
| 2022-02-03 | Fitzgerald Kevin Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.72 | 40.8K | 15,000 | — | ↗ |
| 2022-02-03 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.72 | 40.8K | 15,000 | — | ↗ |
| 2022-02-03 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.72 | 40.8K | 15,000 | — | ↗ |
| 2021-10-06 | Fitzgerald Kevin Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.44 | 103.2K | 30,000 | — | ↗ |
| 2021-07-14 | Rakhit Amit | Officer | M-Exempt | A | Common Stock | 34,017 | 1.89 | 64.3K | 760,840 | — | ↗ |
| 2021-07-09 | Poole Robert Michael | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.94 | 118.2K | 30,000 | — | ↗ |
| 2021-07-01 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 3.95 | 197.5K | 50,000 | — | ↗ |
| 2021-06-11 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.49 | 67.4K | 15,000 | — | ↗ |
| 2021-06-11 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.49 | 67.4K | 15,000 | — | ↗ |
| 2021-06-11 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.49 | 67.4K | 15,000 | — | ↗ |
| 2021-06-02 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 4.42 | 442.0K | 100,000 | — | ↗ |
| 2021-05-17 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 1,750 | 3.67 | 6.4K | 1,750 | — | ↗ |
| 2021-05-17 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 1,750 | 3.67 | 6.4K | 1,750 | — | ↗ |
| 2021-05-17 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 1,750 | 3.67 | 6.4K | 1,750 | — | ↗ |
| 2021-05-17 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 1,750 | 3.67 | 6.4K | 1,750 | — | ↗ |
| 2021-02-05 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 7.40 | 555.0K | 75,000 | — | ↗ |
| 2020-12-17 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.82 | 493.5K | 175,000 | — | ↗ |
| 2020-12-17 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.82 | 493.5K | 175,000 | — | ↗ |
| 2020-12-17 | Rakhit Amit | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 2.82 | 564.0K | 200,000 | — | ↗ |
| 2020-12-17 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.82 | 493.5K | 175,000 | — | ↗ |
| 2020-12-17 | LEVIN JEREMY M | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 650,000 | 2.82 | 1.83M | 650,000 | — | ↗ |
| 2020-12-17 | Haasner Dirk | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.82 | 282.0K | 100,000 | — | ↗ |
| 2020-12-17 | Daly Timothy | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 2.82 | 352.5K | 125,000 | — | ↗ |
| 2020-11-25 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 44,000 | 3.66 | 161.0K | 44,000 | — | ↗ |
| 2020-11-25 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 44,000 | 3.66 | 161.0K | 44,000 | — | ↗ |
| 2020-10-11 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.65 | 113.0K | 20,000 | — | ↗ |
| 2020-10-11 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.65 | 113.0K | 20,000 | — | ↗ |
| 2020-10-11 | Haasner Dirk | Officer | A-Award | A | Stock option (Right to Buy) | 20,000 | 5.65 | 113.0K | 20,000 | — | ↗ |
| 2020-09-30 | Rona Jeffrey A | Officer | A-Award | A | Stock Option (Right to Buy) | 325,000 | 5.74 | 1.87M | 325,000 | — | ↗ |
| 2020-08-28 | LEVIN JEREMY M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 8,488 | 5.84 | 49.6K | 5,792,530 | — | ↗ |
| 2020-06-19 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 7.40 | 370.0K | 50,000 | — | ↗ |
| 2020-06-05 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 13,250 | 5.29 | 70.1K | 13,250 | — | ↗ |
| 2020-06-05 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 13,250 | 5.29 | 70.1K | 13,250 | — | ↗ |
| 2020-06-05 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 13,250 | 5.29 | 70.1K | 13,250 | — | ↗ |
| 2020-06-05 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 13,250 | 5.29 | 70.1K | 13,250 | — | ↗ |
| 2020-01-01 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 4.15 | 311.3K | 75,000 | — | ↗ |
| 2019-12-18 | Rakhit Amit | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 4.42 | 884.0K | 200,000 | — | ↗ |
| 2019-12-18 | Perone Thomas Michael | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 4.42 | 442.0K | 100,000 | — | ↗ |
| 2019-12-18 | LEVIN JEREMY M | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 600,000 | 4.42 | 2.65M | 600,000 | — | ↗ |
| 2019-12-18 | Haasner Dirk | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 4.42 | 442.0K | 100,000 | — | ↗ |
| 2019-12-18 | Daly Timothy | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 4.42 | 552.5K | 125,000 | — | ↗ |
| 2019-11-18 | Tardio Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 2.76 | 345.0K | 125,000 | — | ↗ |
| 2019-11-13 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (right to buy) | 7,437 | 2.43 | 18.1K | 7,437 | — | ↗ |
| 2019-11-13 | Friedman Bart | Director | A-Award | A | Stock Option (right to buy) | 7,437 | 2.43 | 18.1K | 7,437 | — | ↗ |
| 2019-11-13 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (right to buy) | 7,437 | 2.43 | 18.1K | 7,437 | — | ↗ |
| 2019-11-13 | Bernstein Karen | Director | A-Award | A | Stock Option (right to buy) | 7,437 | 2.43 | 18.1K | 7,437 | — | ↗ |
| 2019-11-01 | Rakhit Amit | Officer | A-Award | A | Common Stock (right to buy) | 75,000 | 2.46 | 184.5K | 75,000 | — | ↗ |
| 2019-11-01 | Daly Timothy | Officer | A-Award | A | Employee stock option (right to buy) | 25,000 | 2.46 | 61.5K | 25,000 | — | ↗ |
| 2019-10-08 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | P-Purchase | A | Common Stock | 2,000,000 | 2.50 | 5.00M | 5,750,000 | — | ↗ |
| 2019-10-08 | LEVIN JEREMY M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 60,000 | 2.50 | 150.0K | 4,736,529 | — | ↗ |
| 2019-09-20 | LEVIN JEREMY M | Director / Officer | G-Gift | D | Common Stock | 465,116 | 0.00 | — | 0 | — | ↗ |
| 2019-06-10 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 1.65 | 9.6K | 5,813 | — | ↗ |
| 2019-06-10 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 1.65 | 9.6K | 5,813 | — | ↗ |
| 2019-06-10 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 1.65 | 9.6K | 5,813 | — | ↗ |
| 2019-06-10 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 1.65 | 9.6K | 5,813 | — | ↗ |
| 2019-06-07 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 1.60 | 9.3K | 5,813 | — | ↗ |
| 2019-06-07 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 1.60 | 9.3K | 5,813 | — | ↗ |
| 2019-06-07 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 1.60 | 9.3K | 5,813 | — | ↗ |
| 2019-04-03 | Perone Thomas Michael | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 1.92 | 240.0K | 125,000 | — | ↗ |
| 2019-04-01 | Rakhit Amit | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 1.76 | 88.0K | 50,000 | — | ↗ |
| 2019-04-01 | During Matthew | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.76 | 132.0K | 75,000 | — | ↗ |
| 2019-03-25 | Perone Thomas Michael | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-26 | Bernstein Karen | Director | P-Purchase | A | Common Stock | 10,000 | 2.02 | 20.2K | 20,000 | — | ↗ |
| 2019-02-24 | Ward Ana | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 1.89 | 75.6K | 40,000 | — | ↗ |
| 2019-02-24 | Rakhit Amit | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 1.89 | 236.3K | 125,000 | — | ↗ |
| 2019-02-24 | LEVIN JEREMY M | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 1.89 | 472.5K | 250,000 | — | ↗ |
| 2019-02-24 | Haasner Dirk | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 1.89 | 141.8K | 75,000 | — | ↗ |
| 2019-02-24 | During Matthew | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 1.89 | 132.3K | 70,000 | — | ↗ |
| 2019-02-24 | Daly Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 1.89 | 94.5K | 50,000 | — | ↗ |
| 2019-02-22 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | — | I | Series A Convertible Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-22 | LEVIN JEREMY M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 75,000 | 2.00 | 150.0K | 4,676,529 | — | ↗ |
| 2018-08-27 | Ward Ana | Officer | A-Award | A | Employee Stock Option (right to buy) | 11,250 | 6.40 | 72.0K | 11,250 | — | ↗ |
| 2018-08-27 | Rakhit Amit | Officer | A-Award | A | Employee Stock Option (right to buy) | 70,000 | 6.40 | 448.0K | 70,000 | — | ↗ |
| 2018-08-27 | Haasner Dirk | Officer | A-Award | A | Employee Stock Option (right to buy) | 22,500 | 6.40 | 144.0K | 22,500 | — | ↗ |
| 2018-08-27 | Daly Timothy | Officer | A-Award | A | Employee Stock Option (right to buy) | 11,250 | 6.40 | 72.0K | 11,250 | — | ↗ |
| 2018-08-14 | WILLIAMS DOUGLAS E | Director | P-Purchase | A | Common Stock | 5,000 | 6.49 | 32.4K | 5,000 | — | ↗ |
| 2018-08-14 | Bernstein Karen | Director | P-Purchase | A | Common Stock | 10,000 | 6.23 | 62.3K | 10,000 | — | ↗ |
| 2018-06-07 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 8.12 | 47.2K | 5,813 | — | ↗ |
| 2018-06-07 | Friedman Bart | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 8.12 | 47.2K | 5,813 | — | ↗ |
| 2018-06-07 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 8.12 | 47.2K | 5,813 | — | ↗ |
| 2018-06-07 | Bernstein Karen | Director | A-Award | A | Stock Option (Right to Buy) | 5,813 | 8.12 | 47.2K | 5,813 | — | ↗ |
| 2018-01-19 | Werber Yaron | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 131,000 | 9.18 | 1.20M | 131,000 | — | ↗ |
| 2018-01-19 | Ward Ana | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 9.18 | 183.6K | 20,000 | — | ↗ |
| 2018-01-19 | Rakhit Amit | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 95,000 | 9.18 | 872.1K | 95,000 | — | ↗ |
| 2018-01-19 | LEVIN JEREMY M | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 290,000 | 9.18 | 2.66M | 290,000 | — | ↗ |
| 2018-01-19 | Haasner Dirk | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 30,000 | 9.18 | 275.4K | 30,000 | — | ↗ |
| 2018-01-19 | During Matthew | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 110,000 | 9.18 | 1.01M | 110,000 | — | ↗ |
| 2018-01-19 | Daly Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 30,000 | 9.18 | 275.4K | 30,000 | — | ↗ |
| 2017-09-05 | Ward Ana | Officer | A-Award | A | Stock Option Grant (Right to Buy) | 95,000 | 8.38 | 796.1K | 95,000 | — | ↗ |
| 2017-09-01 | Ward Ana | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-25 | LEVIN JEREMY M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 15,334 | 7.15 | 109.6K | 4,601,529 | — | ↗ |
| 2017-06-14 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 11,627 | 13.91 | 161.7K | 11,627 | — | ↗ |
| 2017-05-10 | Werber Yaron | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 93,022 | 8.50 | 790.7K | 93,022 | — | ↗ |
| 2017-05-10 | LEVIN JEREMY M | Director / Officer / 10% Owner | C-Conversion | D | Series A Preferred Stock | 400,150 | 0.00 | — | 0 | — | ↗ |
| 2017-05-10 | During Matthew | Director / Officer / 10% Owner | C-Conversion | D | Series A Preferred Stock | 28,245 | 0.00 | — | 0 | — | ↗ |
| 2017-05-10 | Daly Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 46,510 | 8.50 | 395.3K | 46,510 | — | ↗ |
| 2017-05-04 | Werber Yaron | Officer | — | D | Employee Stock Option (Right to Buy) | 89,302 | 8.50 | 759.1K | 0 | — | ↗ |
| 2017-05-04 | WILLIAMS DOUGLAS E | Director | — | D | Stock Option (Right to Buy) | 11,909 | 8.50 | 101.2K | 0 | — | ↗ |
| 2017-05-04 | Rakhit Amit | Officer | — | D | Employee Stock Option (Right to Buy) | 232,558 | 8.35 | 1.94M | 0 | — | ↗ |
| 2017-05-04 | LEVIN JEREMY M | Director / Officer / 10% Owner | — | I | Series B Preferred Stock | 35,461 | 0.00 | — | 0 | — | ↗ |
| 2017-05-04 | Haasner Dirk | Officer | — | D | Employee Stock Option (Right to Buy) | 44,650 | 8.50 | 379.5K | 0 | — | ↗ |
| 2017-05-04 | Friedman Bart | Director | — | D | Stock Option (Right to Buy) | 10,260 | 6.26 | 64.2K | 0 | — | ↗ |
| 2017-05-04 | During Matthew | Director / Officer / 10% Owner | — | D | Employee Stock Option (Right to Buy) | 74,418 | 6.26 | 465.9K | 0 | — | ↗ |
| 2017-05-04 | Daly Timothy | Officer | — | D | Employee Stock Option (Right to Buy) | 46,511 | 8.35 | 388.4K | 0 | — | ↗ |
| 2017-05-04 | Bernstein Karen | Director | — | D | Stock Option (Right to Buy) | 58,139 | 8.35 | 485.5K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-18.5K
Shares Outstanding
131.88M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jeremy M. Levin, DPhil, MB BChir Executive Chairman and Former Chief Executive Officer | 644.1K | — | — | 744.6K | 532.0K | 14.0K | 1.93M | 38.49% | ↗ |
| 2 | 2025 | Margaret Alexander President and Chief Executive Officer and Former Chief Operating Officer | 515.0K | — | 24.8K | 118.5K | 350.0K | 14.0K | 1.02M | 14.02% | ↗ |
| 3 | 2025 | Jeffrey Rona Chief Business & Financial Officer | 506.9K | — | 24.8K | 118.5K | 305.0K | 14.0K | 969.2K | 14.78% | ↗ |
| 4 | 2024 | Jeremy M. Levin, DPhil, MB BChir Chief Executive Officer | 625.3K | — | — | 1.84M | 292.3K | 13.8K | 2.77M | 66.42% | ↗ |
| 5 | 2024 | Jeremy M. Levin, DPhil, MB BChir Executive Chairman and Former Chief Executive Officer | 625.3K | — | — | 1.84M | 292.3K | 13.8K | 2.77M | 66.42% | ↗ |
| 6 | 2024 | Margaret Alexander President and Chief Executive Officer and Former Chief Operating Officer | 484.4K | — | 103.5K | 821.9K | 231.5K | 13.8K | 1.66M | 55.91% | ↗ |
| 7 | 2024 | Margaret Alexander President and Chief Operating Officer | 484.4K | — | 103.5K | 821.9K | 231.5K | 13.8K | 1.66M | 55.91% | ↗ |
| 8 | 2024 | Jeffrey Rona Chief Business & Financial Officer | 492.1K | — | 103.5K | 703.1K | 206.3K | 13.8K | 1.52M | 53.11% | ↗ |
| 9 | 2023 | Jeremy Levin, DPhil, MB BChir Chief Executive Officer | 625.3K | — | — | 1.11M | 390.8K | 13.9K | 2.14M | 51.79% | ↗ |
| 10 | 2023 | Jeremy M. Levin, DPhil, MB BChir Chief Executive Officer | 597.0K | — | — | 1.11M | 390.8K | 13.2K | 2.11M | 52.50% | ↗ |
| 11 | 2023 | Thomas M. Perone General Counsel & Corporate Secretary | 494.9K | — | — | 322.7K | 237.6K | 13.2K | 1.07M | 30.21% | ↗ |
| 12 | 2023 | Jeffrey Rona Chief Business & Financial Officer | 469.3K | — | — | 322.7K | 255.9K | 13.2K | 1.06M | 30.42% | ↗ |
| 13 | 2022 | Jeremy Levin, DPhil, MB BChir Chief Executive Officer | 607.1K | — | — | 2.20M | 303.5K | 12.9K | 3.13M | 70.47% | ↗ |
| 14 | 2022 | Jeffrey Rona Chief Business & Financial Officer | 473.2K | — | — | 923.1K | 189.3K | 23.8K | 1.61M | 57.36% | ↗ |
| 15 | 2022 | Jason Tardio, MBA Chief Operating Officer | 457.6K | — | — | 581.0K | 183.0K | 12.2K | 1.23M | 47.09% | ↗ |
| 16 | 2021 | Jeffrey Rona Chief Business & Financial Officer | 455.0K | — | — | 320.6K | 197.7K | — | 973.3K | 32.94% | ↗ |
| 17 | 2021 | Jeremy Levin, DPhil, MB BChir. Chief Executive Officer | 583.7K | — | — | — | 251.7K | 11.6K | 856.9K | 0.00% | ↗ |
| 18 | 2021 | Jeremy Levin, DPhil, MB BChir Chief Executive Officer | 583.7K | — | — | — | 251.7K | 11.6K | 847.1K | 0.00% | ↗ |
| 19 | 2021 | Thomas M. Perone, JD, MBA General Counsel & Corporate Secretary | 457.6K | — | — | — | 162.9K | 11.6K | 638.1K | 0.00% | ↗ |
| 20 | 2020 | Jeremy Levin, DPhil, MB BChir. Chief Executive Officer | 560.0K | — | — | 1.27M | 280.0K | 21.2K | 2.14M | 59.67% | ↗ |
| 21 | 2020 | Jeffrey Rona Chief Business & Financial Officer | 107.9K | — | — | 1.71M | 170.0K | 923.00 | 1.99M | 85.98% | ↗ |
| 22 | 2020 | Jeffrey Rona Chief Business Officer | 107.9K | — | — | 1.71M | 170.0K | 922.00 | 1.99M | 85.98% | ↗ |
| 23 | 2020 | Thomas M. Perone, JD, MBA General Counsel & Corporate Secretary | 440.0K | — | — | 842.1K | 176.0K | 17.4K | 1.48M | 57.07% | ↗ |
| 24 | 2019 | Jeremy Levin, DPhil, MB BChir. Chief Executive Officer | 530.5K | — | — | 2.19M | 265.2K | 25.6K | 3.01M | 72.70% | ↗ |
| 25 | 2019 | Amit Rakhit, M.D., MBA President & CMO | 481.0K | — | — | 896.9K | 199.8K | 13.3K | 1.59M | 56.37% | ↗ |
| 26 | 2019 | Timothy Daly EVP, Finance, Corporate Controller & Treasurer | 309.0K | — | — | 457.8K | 115.2K | 15.3K | 897.3K | 51.02% | ↗ |
| 27 | 2018 | Jeremy Levin, DPhil, MB BChir. Chief Executive Officer | 530.5K | — | — | 1.91M | 200.0K | 23.7K | 2.66M | 71.66% | ↗ |
| 28 | 2018 | Amit Rakhit, M.D., MBA CMO, Head of Research and Development | 437.0K | — | — | 879.4K | 219.0K | 12.7K | 1.55M | 56.80% | ↗ |
| 29 | 2018 | Amit Rakhit, M.D., MBA President & CMO | 437.0K | — | — | 879.4K | 219.0K | 12.7K | 1.55M | 56.80% | ↗ |
| 30 | 2018 | Mathew During, MD, DSc Former President and Chief Scientific Officer | 477.4K | — | — | 723.5K | 174.0K | 18.5K | 1.39M | 51.92% | ↗ |
| 31 | 2017 | Jeremy Levin, DPhil, MB BChir. Chief Executive Officer | 515.0K | — | — | 1.38M | 218.9K | 10.8K | 2.13M | 65.03% | ↗ |
| 32 | 2017 | Yaron Werber, MD, MBA Chief Business and Financial Officer and Treasurer | 412.0K | — | — | 1.09M | 125.5K | 10.2K | 1.63M | 66.47% | ↗ |
| 33 | 2017 | Mathew During, MD, DSc Former President and Chief Scientific Officer | 463.5K | — | — | 947.3K | 161.3K | 4.5K | 1.58M | 60.09% | ↗ |
| 34 | 2017 | Mathew During, MD, DSc President and Chief Scientific Officer | 463.5K | — | — | 947.3K | 161.3K | 4.5K | 1.58M | 60.09% | ↗ |
| 35 | 2016 | Jeremy Levin, DPhil, MB BChir. Chief Executive Officer | 500.0K | — | — | 784.3K | 250.0K | 5.0K | 1.54M | 50.95% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeremy Max Levin Ba Zoology Dphil Mb Bchir | Co-Founder & Executive Chairman | 1M | — |
| Margaret Alexander | CEO, President & Director | 879.0K | female |
| Jeffrey A. Rona | Chief Business & Financial Officer and Corporate Secretary | 825.9K | male |
| Petra Kaufmann | Chief Medical Officer | — | — |
| Tom Parry | Vice President of Research and Early Development | — | male |
| Toshiya Nishi | Head of Epilepsy Research | — | — |
| Victoria Fort | Senior Vice President of Corporate Affairs & Corporate Strategy | — | female |
| Charles Ross Carter | Senior Vice President of Finance & Financial Planning | — | male |
| Zhong Zhong | Chief Scientific Officer | — | male |
| Julia Tsai | Senior Vice President of Clinical Development | — | — |
| Manal Morsy | Chief Regulatory Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OVID
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
